Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

Fintel reports that on August 4, 2025, Oppenheimer upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from Perform to Outperform. Analyst Price Forecast Suggests 18.88% Downside As of ...

On May 2, Alnylam Pharmaceuticals reveals figures for the most recent quarter. Wall Street analysts expect Alnylam Pharmaceuticals will be reporting losses per share of $1.116.

Decline in Revenue: Over the 3 months period, Alnylam Pharmaceuticals faced challenges, resulting in a decline of approximately -33.26% in revenue growth as of 30 September, 2024.

In the last 3 months, 9 analysts have offered 12-month price targets for Alnylam Pharmaceuticals. The company has an average price target of $209.67 with a high of $273.00 and a low of $108.00.

For Alnylam Pharmaceuticals, the 200-day moving average sits at $183.94, according to Benzinga Pro, which is above the current price of $150.75. For more on charts and trend lines, see a ...

Present Market Standing of Alnylam Pharmaceuticals With a volume of 918,360, the price of ALNY is up 1.19% at $257.76. RSI indicators hint that the underlying stock may be overbought.

Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 51% in a month.

What happened Shares of Alnylam Pharmaceuticals (ALNY 1.02%) were tanking on Thursday after the company reported its earnings results for the third quarter.

Alnylam Pharmaceuticals has seen its stock rise by 17% this year. The stock now trades at over 33x projected 2020 revenues, despite the fact that the company is likely to post another loss this year.